War fa rin in hemodialysis pa tients Ab stract. Back ground: There is a pau city of data con cern ing the risks as so ci ated with war fa rin in hemodialysis (HD) pa tients. We com pared ma jor bleed ing ep i sodes in this group with HD pa tients not re ceiv ing war farin and with a co hort of non-HD pa tients receiv ing war fa rin. Meth ods: A ret ro spec tive review of 141 HD pa tients on war fa rin (HDW), 704 HD pa tients not on war fa rin (HDNW) and 3,266 non-di al y sis war fa rin patients (NDW) was per formed. Hos pi tal ad missions for hem or rhagic events and ischemic strokes were ex am ined as was hos pi tal length of stay and blood prod uct use. INR vari abil ity was also as sessed. Re sults: The in ci dence rates for ma jor hem or rhage per 100 pa tient years was 10.8 in the HDW group as compared to 8.0 in the HDNW (p = 0.593) and 2.1 in the NDW (p < 0.001) groups. Mean units of red blood cell trans fu sions re quired was higher in pa tients on di al y sis with no sig nif icant dif fer ence be tween HDW and HDNW groups. The risk of ischemic stroke per 100 pa tient years was 1.7 in the HDW group as com pared to 0.7 in the HDNW groups (p = 0.636) and 0.4 in the NDW (p = 0.003). The HDW group had higher inter-measurement INR vari abil ity com pared to the NDW group (p = 0.034). In pa tients with atrial fi bril la tion, HDW group had a higher in ci dence of ischemic stroke than the NDW group (2.2 ver sus 0.4 events per 100 pa tient years; p = 0.024). Con clu sions: This study con firms the higher bleed ing risk as so ci ated with HD/ESRD but sug gests that war fa rin use in these pa tients may not add sig nif i cantly to this risk. We also dem on strated high rates of ischemic stroke in HD pa tients de spite war farin use. Sum mary: Our study com pares the fre quency of ma jor hem or rhage and sec ondarily, ischemic stroke in HD pa tients re ceiving or not re ceiv ing war fa rin, with non-HD pa tients re ceiv ing war fa rin. The ma jor finding was that fre quency of hem or rhage was higher in HD pa tients re ceiv ing war fa rin than in non-HD pa tients re ceiv ing war fa rin, but not dif fer ent in HD pa tients with or with out war fa rin. A sec ond ary find ing was that INR vari abil ity was sig nif i cantly higher in HD patients than non-HD pa tients on war fa rin.
Introduction
Ure mia leads to an in creased risk of bleeding due to platelet dys func tion and al tered platelet ag gre ga tion. Chronic kid ney dis ease (CKD) has been as so ci ated with a higher risk of ma jor bleed ing in pa tients tak ing war fa rin [1] . Hemodialyosis (HD) pa tients are ad dition ally at risk of thrombo-embolic phe nomena such as vas cu lar ac cess throm bosis. More over, the prev a lence of atrial fi bril la tion is es ti mated at 25% in HD pa tients [2] . This ex plains the com mon use of war fa rin anticoagulation in the HD set ting.
War fa rin is as so ci ated with ap pre cia ble lev els of hem or rhagic ad verse events in the gen eral pop u la tion [3] but its use in end-stage re nal dis ease (ESRD) pa tients has never been fully eval u ated. Holden et al. showed an increase in ma jor bleed ing ep i sodes in HD patients who were pre scribed as pi rin with or with out war fa rin [4] . There was also more bleed ing in those tak ing war fa rin alone compared with di al y sis pa tients tak ing nei ther aspi rin nor war fa rin, but this did not reach statis ti cal sig nif i cance. Re cently, the in flu ence of CKD on the hem or rhagic com pli ca tions of war fa rin was ex am ined [5] . It was re ported that CKD pa tients re quired a lower dose of war fa rin, had in sta bil ity of the INR and had a higher risk for ma jor hem or rhage. How ever, only 53 of the to tal 565 pa tients had Stage IV or V CKD. We aimed to es tab lish the risk of hem or rhage with war fa rin use in our chronic HD pop u la tion and to com pare this group to both di al y sis pa tients not taking warfarin and non-dialysis patients who were receiving warfarin anticoagulation.
Materials and methods

Subjects
Our in sti tu tion is the larg est di al y sis center in the Re pub lic of Ire land with 220 prev alent pa tients. We ex am ined prev a lent, adult (³ 18 years), HD pa tients who re ceived warfa rin treat ment for a pe riod of at least one month, for any in di ca tion, be tween Jan u ary 1st, 2000 and No vem ber 30th, 2008. We compared this group to all adult HD pa tients during this pe riod who had never re ceived war farin. Only pa tients com plet ing at least 90 days of HD were in cluded in the HD groups. We also com pared these pa tients to a co hort from the gen eral pop u la tion war fa rin clinic. These were all adult pa tients who were main tained on war fa rin for any in di ca tion for at least 1 month dur ing the same time pe riod. Pa tients were followed from ini ti a tion of war fa rin un til death, trans plan ta tion, trans fer to PD, trans fer to another cen ter or un til the De cem ber 31st, 2008. The date of the first di al y sis ses sion was selected as the be gin ning of war fa rin ex po sure when the pa tient was tak ing war fa rin prior to the ini ti a tion of di al y sis. HD was pro vided using Gambro sys tems (AK 200 se ries ma chines with Polyflux dialyzers). Stan dard anticoagulation dur ing di al y sis was de liv ered us ing unfractionated hep a rin, gen er ally at a dose of 3,000 -5,000 i.u. per treat ment.
Data collection
We ac cessed data from our Nephrology pa tient da ta base (Clin i cal Vi sion 3.4a Ver sion 1.1.34.1), the blood bank da ta base (Mediware HCLL Ver sion 2.9.3 ac cessed via Prodiver Ver sion 5.1), the war fa rin clinic data base (dabl An ti co ag u lant) and HIPE (Hospital InPatient En quiry) coded re cords. ICD-9 codes were used up to 2004 with ICD-10 codes used there af ter. The top five di ag no ses were ex amined and these coded re cords were then in divid u ally ad ju di cated by chart re view to ensure the event was a main rea son for hos pi tal ad mis sion or ex tended the stay if a bleed was iden ti fied that oc curred dur ing a pri mary admis sion for an other cause. A ma jor hem orrhage was de fined as any bleed ing ep i sode which re quired hos pi tal iza tion (³ 1 day) and were classed as gas tro-in tes ti nal, intra-cranial, ENT/re spi ra tory, or other hem or rhages. Only one hem or rhagic di ag no sis was used for each in pa tient stay. Ischemic stroke was de fined (us ing ICD codes) as any non-hemorrhagic stroke which re quired hos pi tal ad mis sion. The need for blood prod ucts in clud ing packed red cells and plasma were ex am ined for the 3 groups and linked to each ad mis sion.
Outcomes
The pri mary out come was de fined as consist ing of ma jor bleed ing ep i sodes i.e. as any hem or rhage ne ces si tat ing hos pi tal ad mission. We con sid ered events to have oc curred on war fa rin treat ment when they oc curred while the pa tient was re ceiv ing war fa rin or within 30 days of war fa rin ces sa tion. Sec ondary out come mea sures ex am ined were: ischemic stroke rate, num ber of units of packed red cells and plasma trans fused, INR vari abil ity and hospital length of stay.
Statistical analysis
In ci dence rates were cal cu lated as the num ber of ma jor bleed ing events di vided by the to tal time of fol low up/war fa rin ex po sure. Pois son re gres sion mod els ad justed for ex posure time were used to com pare in ci dence rates be tween groups. A multifactorial model in cluded and ad justed for the con found ing vari ables age and sex. A mul ti ple com par i son Bonferroni cor rec tion was used to allow for sub group analysis.
It is well es tab lished that war fa rin has many food and drug in ter ac tions [6] which can lead to dif fi culty con trol ling prothrombin time. As HD pa tients who are anticoagulated have fre quent mea sure ments of the INR (at least weekly at our cen ter), it may be ex pected that they ex pe ri ence less vari a tion of the INR. To test for INR vari abil ity, we used a vari ability score pro posed by Fihn et al. [7] and recently adapted by Limdi et al. [5] . This score ad justs for dif fer ing fre quency of vis its and the in ter val be tween vis its on INR vari a tion for each pa tient. As pa tients had dif fer ent tar get ranges de pend ing on the in di ca tion for anticoagulation we have adapted the for mula slightly, us ing the vari a tion around the mean INR re corded.
Sta tis ti cal anal y sis was per formed us ing Stata (ver sion 10, Col lege Sta tion, TX, USA). A p value < 0.05 was deemed to be sta tis tically sig nif i cant for re sults in our study.
Results
The three groups used for anal y sis were HDW (di al y sis war fa rin; 141 pa tients), HDNW (di al y sis non-war fa rin; 704 pa tients) and NDW (non-di al y sis war fa rin; 3,266 patients). To tal fol low up/ex po sure time was 285 pa tient years (mean 2.02 years), 1,344 pa tient years (mean 1.91 years) and 10,007 pa tient years (mean 3.06 years) re spec tively. Base line de mo graphic characteristics are shown in Table 1. The mean age was sig nif i cantly older in the two groups of pa tients re ceiv ing war fa rin com pared to the HDNW group (p = 0.0001). Also, the HDW group had pro por tion ally more fe males with 52/48% male/fe male ra tio. The HDNW group had a 64/36% male/fe male split which is con sis tent with the wider ESRD pop u la tion in Ire land [Re nal Dis ease in Ireland -A Stra te gic Re view (un pub lished)]. The com mon est in di ca tions for war fa rin were atrial fi bril la tion, fol lowed by ve nous thromboembolism (in clud ing deep ve nous throm bo sis and pul mo nary em bo lism) in both groups receiv ing war fa rin. Only 6.3% of the HDW group were pre scribed war fa rin for pre vention of ac cess throm bo sis (Ta ble 1). The mean INR dur ing the ex po sure time was 2.05 (SD 0.44) in the HDW group com pared to 2.54 (SD 0.83) in the NDW group (p < 0.0001).
Major bleeding complications
For the HDW group, there were a to tal of 31 ma jor bleed ing ep i sodes giv ing an in cidence rate of 10.8 ma jor bleeds per 100 patient years. By com par i son, the HDNW group ex pe ri enced 108 bleeds (8.0 per 100 pa tient years; p = 0.593) and the NDW group had 209 ma jor bleeds (2.1 per 100 pa tient years; p < 0.001). The dif fer ence in rates of bleed ing between NDW and HDNW groups was also statis ti cally significant (p < 0.001). Figure 1 shows the in ci dence rates of the dif fer ent types of hem or rhagic com pli cations. Intracranial hem or rhage was un common and did not oc cur in any of the di al y sis pa tients tak ing war fa rin. The "Other bleeds" cat e gory ac counted for a sig nif i cantly larger pro por tion of bleeds in the di al y sis groups, par tic u larly in the HDW group (p = 0.053 versus HDNW; p < 0.001 ver sus NDW). "Other bleeds" were com prised of gynecological NDW = non-di al y sis war fa rin; HDW = hemodialysis war fa rin; HDNW = hemodialysis non-war fa rin; SD = stan dard de vi a tion; VTE = ve nous thrombo embolism (com pris ing DVT and PE); GI = gas tro in tes ti nal; CNS = cen tral ner vous sys tem; ENT/RESP = ear nose throat/re spi ra tory; CVA = cerebrovascular ac ci dent; LOS = hos pi tal length of stay for ma jor hem or rhage ad mis sions. *p value be tween Groups 1 and 2, # p value be tween Groups 1 and 3.
bleed ing, ma jor hematuria, un spec i fied bleeding and bleed ing af ter a pro ce dure.
Blood product requirements
We ex am ined blood prod uct re quire ments dur ing each hos pi tal ad mis sion for a hem orrhagic com pli ca tion. For red cells, ap prox imately half of both di al y sis groups re quired blood com pared to al most one quar ter of the NDW group (Table 3 ) (p < 0.001). Mean red cell units trans fused were 1.23 units per patient in the HDW group com pared to 1.76 units per pa tient in the HDNW group (p = 0.007) and 0.50 units per pa tient in the NDW group (p < 0.001). The pro por tion of pa tients re quir ing plasma trans fu sions were not sta tisti cally dif fer ent be tween the groups (p = 0.059 be tween HDW and NDW). Both di al ysis groups re ceived a sim i lar amount of plasma units which was higher than the NDW group but not sig nif i cantly so (p = 0.350).
Ischemic strokes
The over all in ci dence rate of ischemic strokes in all HD pa tients was 0.9 events per 100 pa tient years. There was an in ci dence rate of 1.7 ischemic strokes per 100 pa tient years in the HDW group com pared to a rate of 0.4 events per 100 pa tient years in the NDW group (rate ra tio 5.07; p = 0.003) (Ta ble 2). The in ci dence rate in the HDNW pa tients was lower than that in the HDW group at 0.7 ischemic strokes per 100 pa tient years (rate ra tio 1.80; p = 0.636) but higher than the NDW group (rate ra tio 1.63; p = 0.024).
When we com pared only atrial fi bril la tion pa tients in the two war fa rin groups, there was a higher in ci dence of ischemic stroke in the HD pa tient group as com pared to the nondialysis group (2.2 vs. 0.4 events per 100 patient years, rate ra tio 5.52; p = 0.024) (Figure 2 ).
Hospital length of stay
Mean length of stay for hos pi tal ad missions due to bleed ing was also ex am ined. There was no sta tis ti cally sig nif i cant dif ference be tween the groups, with HDW hav ing a Bleed ing in ci dence rates per pa tient group. NDW = non-di al y sis war fa rin; HDW = hemodialysis war fa rin; HDNW = hemodialysis non-war farin; GI = gas tro in tes ti nal; CNS = cen tral ner vous sys tem; ENT/RESP = ear nose throat/re spi ra tory.
Ta ble 2. Com par i son of out comes for the three groups ex pressed as in ci dence rates (events per 100 pa tient years). NDW = non-di al y sis war fa rin; HDW = hemodialysis war fa rin; HDNW = hemodialysis non-war fa rin; GI = gas tro in tes ti nal; CNS = cen tral ner vous sys tem; ENT/RESP = ear nose throat/re spi ra tory; CVA = cerebrovascular ac ci dent; LOS = hos pi tal length of stay for ma jor hem or rhage ad mis sions. *p value be tween Groups 2 and 3.
Ta ble 3. Com par i son of blood prod ucts re quired dur ing hos pi tal ad mis sions for ma jor hem or rhage. 
INR variability
The INR vari abil ity be tween vis its was cal cu lated as per the meth ods de scribed above. HDW group had more fre quent checks of their INR (mean ev ery 13.4 days) compared to the NDW group (mean ev ery 36.4 days). How ever, the mean vari abil ity was 0.25 INR units in the NDW group as compared to 0.71 INR units in the HDW group (p = 0.034).
Discussion
There is a pau city of data con cern ing risks of ma jor hem or rhage in HD pa tients re ceiving treat ment with war fa rin. This is dem onstrated by a re cent sys tem atic re view of the sub ject in which only five stud ies met ini tial in clu sion cri te ria [8] . Only three small stud ies were ran dom ized con trolled tri als and the indi ca tion for war fa rin was pre ven tion of access throm bo sis. The vast ma jor ity of our patients were re ceiv ing anticoagulation for a rea son other than pre ven tion of ac cess thrombo sis. This study il lus trates the high risk of ma jor bleed ing events in HD pa tients, ir respec tive of oral anticoagulation. The in ci dence rate of ma jor hem or rhagic events in all HD pa tients at our cen ter was 8.5 per 100 pa tient years. The com mon est bleed ing site was the GI tract, closely fol lowed by ENT/respi ra tory bleeds. How ever, as a group, other or mis cel la neous bleeds com prised the larg est group in the di al y sis pa tients treated with war fa rin. Mul ti ple bleed ing sites contributed to this group in cluding bleeding post procedure and gyneco logical bleeding.
Over all, the use of war fa rin in our HD pop u la tion ap peared to be safer than we were ini tially ex pect ing. There were no re corded intracranial hem or rhages in this pa tient group and length of hos pi tal stay was equiv a lent to the other groups. More over, to tal ma jor bleed ing ep i sodes did not oc cur more commonly in our HD pa tients re ceiv ing war fa rin com pared to those not anti co agulated. This per haps should not be sur pris ing given the results from Holden et al. show ing a very low rate of intracranial hem or rhage in their HD pa tient group and a non-sig nif i cant dif fer ence in ma jor hem or rhages with war fa rin use. In their study, it was only the as pi rin groups which showed a sta tis ti cally sig nif i cant increase in ma jor hem or rhagic events [4] . Also, in the study from Limdi et al. [5] look ing at war fa rin com pli ca tions strat i fied by de gree of CKD, pa tients with an eGFR < 30 mls/min per 1.73 kg/m 2 had sig nif i cantly higher rates of ma jor bleed ing than those with better re nal func tion. Pa tients with an eGFR of 30 -59 mls/min per 1.73 kg/m 2 and an eGFR > 60 mls/min per 1.73 kg/m 2 had sim i lar rates of bleed ing. This sug gests that fac tors as so ci ated with ad vanced CKD are re spon si ble for the addi tional hem or rhagic risk [5] .
The in ci dence of ma jor hem or rhage in the non-di al y sis pa tients who were treated with war fa rin, at 2.3 per 100 pa tient years was simi lar to other stud ies in pa tients on war fa rin for atrial fi bril la tion [9, 10, 11] . In these stud ies, a ma jor hem or rhage was de fined along sim i lar lines to our study. Both di al y sis groups had a sig nif i cantly higher in ci dence of ma jor hemor rhage in our study. This was true of the HDW pa tients de spite hav ing lower mean INRs com pared to the NDW pa tients. The find ing of sim i lar high rates of bleed ing in the di al y sis groups, ir re spec tive of war fa rin use, again im plies a HD/ESRD ef fect caus ing the high bleed ing rates rather than a war fa rin effect. As well as higher rates of bleed ing, HD pa tients re quired more red blood cell trans fusions dur ing their ad mis sions for hem or rhage com pared to non-ESRD war fa rin pa tients. In fact, the HDNW group ac tu ally re ceived more red cell trans fu sions per pa tients than the HDW group. This may in di cate more severe bleed ing in HD pa tients or may re flect other is sues such as a high phy si cian ten dency to trans fuse HD pa tients who are generally sicker that the general population and with established renal anemia.
Us ing USRDS data [12] , patients with ESRD have been shown to have a sig nif icantly higher risk of ischemic and hem orrhagic stroke com pared to the gen eral pop u lation. The in ci dence of ischemic strokes ob served in our study was con sis tent with pre vi ous stud ies in the gen eral HD pop u lation. These stud ies re ported an in ci dence of ischemic stroke be tween 0.37 and 2.52 ep isodes/100 pa tient years [13, 14, 15] , compared with an in ci dence of 0.9 events/100 patient-years in our study. When we fo cus on the in ci dence of stroke in pa tients with atrial fi bril la tion, we dem on strated that the HD patients had more than 5 times the in ci dence rate of ischemic stroke com pared to the gen eral pop u la tion with atrial fi bril la tion on war fa rin. This may raise ques tions re gard ing the ben efit, or lack of ben e fit of war fa rin use in this group. How ever, to an swer that ques tion we would need to com pare stroke in a HD pop ula tion with atrial fi bril la tion who were not anti-co ag u lated. The ev i dence re gard ing warfa rin use in ESRD pa tients with atrial fi bril lation is con tra dic tory. Re sults from the USRDS DMMS Wave II data in di cated there was an im prove ment in all-cause mor tal ity in pa tients hos pi tal ized for atrial fi bril la tion who were re ceiv ing war fa rin [16] . How ever, Wies holzer et al. dem on strated no ad di tional risk of stroke with atrial fi bril la tion in a HD pa tient co hort and a higher rate of stroke in those treated with war fa rin [17] . Fur thermore, a re cent study in 1,671 in ci dent HD patients with pre-ex ist ing atrial fi bril la tion re ported an in creased risk for new stroke asso ci ated with war fa rin use [18] . This risk was not as so ci ated with tak ing anti-platelet agents. The re sults from our study cer tainly sug gest a high risk of ischemic stroke in HD pa tients with atrial fi bril la tion.
The find ing that di al y sis pa tients have more vari abil ity in their war fa rin con trol may ini tially seem sur pris ing given that this patient group gen er ally has more fre quent INR mea sure ments per formed. How ever, it has been dem on strated pre vi ously that pa tients across a range of CKD stages re quire lower doses of war fa rin and have poorer con trol of anticoagulation com pared with those with an eGFR > 60 mls/min per 1.73 kg/m 2 [5] . They were also at a higher risk for over anti coagulation (INR > 4). The prob a bil ity of poor war fa rin con trol in creased with in creas ing sever ity of CKD. The ex pla na tion for in creased INR vari a tion in ESRD pa tients is not im medi ately ob vi ous. It may be re lated to Vi ta min K de fi ciency which has been de scribed in HD pa tients [19] . An other pos si ble rea son for this find ing in our study is that a dif fer ent cli nician of ten pre scribes war fa rin af ter each INR mea sure ment for HD pa tients. This is in contrast to a cen tral anticoagulation clinic which man ages the gen eral pop u la tion war fa rin con trol us ing a com puter pro gram to as sist dos ing which would likely be ben e fi cial in the HD pop u la tion. Al though not dem on strated in this study, it is obvious that in creased INR variability adds to the risk of hemorrhage as well as to the potential harm from under-anticoagulation.
Our re sults will add to the con tro versy sur round ing war fa rin use in the HD set ting [20, 21, 22] . While we agree that there is no proven ben e fit in sys temic anticoagulation for pre ven tion of ac cess throm bo sis [23, 24] , war fa rin may still have a place for other, more tra di tional in di ca tions. Al most 94% of our HD pa tients re ceived war fa rin for rea sons other than ac cess-re lated in di ca tions. Bleeding com pli ca tions, while high, were sim i lar to other HD pa tients not re ceiv ing war fa rin. While our study does not dem on strate ad ditional risk of bleed ing in HD pa tients re ceiving war fa rin, per haps a larger study would. Also, our study pro vides no in for ma tion as to the po ten tial ben e fit of war fa rin ther apy in this pa tient sub set. Does war fa rin use in HD pa tients re duce the in ci dence of thromboembolism suf fi ciently to jus tify any pos si ble ad di tional risk of harm? This ques tion has not yet been fully an swered but, as men tioned pre vi ously, some stud ies do sug gest that warfa rin in ESRD may be risky [17, 18] . Fu ture stud ies to elu ci date these is sues in the HD pop u la tion should in clude ran dom ized controlled stud ies of war fa rin use in HD pa tients with atrial fi bril la tion and of INR vari abil ity and com pli ca tions when us ing phy si cian directed ver sus com puter programme di rected war fa rin pre scrib ing. More over, newer an tico ag u lant agents such as Dagibatran, which has been shown to be as ef fi ca cious as war farin with a sim i lar or better safety pro file, will likely be come more wide spread in clinical practice. How these drugs, which do not need INR monitoring, will behave in HD/ESRD patients will also need to be investigated.
There are some lim i ta tions to this study. Firstly, we ac knowl edge the in her ent weaknesses of any ret ro spec tive, sin gle cen ter study. Al though all pa tient care, di al y sis treatments and fol low up were pro vided by a single cen ter, it is pos si ble, al though un likely, that a ma jor bleed ing ep i sode may have occurred out side our catch ment area with the pa tient be ing treated in an other cen ter. Moreover, we only in cluded ma jor bleed ing ep isodes in this anal y sis. There fore, mi nor events which did not re quire hos pi tal iza tion, such as bleed ing post re moval of fis tula needles, were not in cluded. Fi nally, the use of anti-platelet agents was not re li ably re corded in the da ta bases, so it was not in cluded in the study. Vari a tions in anti-platelet use could poten tially ac count for differences in bleeding complications between the groups.
In con clu sion, we have con firmed the higher bleed ing risk as so ci ated with HD compared to non-ESRD pa tients re ceiv ing war farin. More over, we dem on strated that HD patients on war fa rin had sim i lar rates of ma jor hem or rhage to HD pa tients not re ceiv ing war fa rin. The need for blood prod ucts dur ing hos pi tal ad mis sions for hem or rhage and length of hos pi tal stay was also sim i lar in these groups. These re sults con firm that HD pa tients are at high risk for bleed ing but suggest that war fa rin use in these pa tients may not add significantly to this risk.
